Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

zilganersen

Phase 3RNA therapy

Ionis Pharmaceuticals

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alexander DiseaseActive, not recruiting

Alexander DiseasePhase 3

Active, not recruiting

Timeline

Expected Milestones

Q3 2034

Phase 3Active, not recruiting

Alexander Disease

NCT04849741

Clinical

Trials by Indication[1]

Alexander Disease2 trials

Zilganersen Expanded Access Program for Individuals With Alexander Disease

Available· Ionis Pharmaceuticals logo

Ionis Pharmaceuticals··NCT07487389

A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients With Alexander Disease

Active, not recruiting· Ionis Pharmaceuticals logo

Ionis Pharmaceuticals·Phase 3·NCT04849741·54 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for zilganersen. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — zilganersen compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for zilganersen. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ionis Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: RNA therapy[2]
Highest Phase: Phase 3[1]
Company: Ionis Pharmaceuticals

Related News